NovoCure (NVCR) Operating Leases (2019 - 2026)

NovoCure (NVCR) has reported Operating Leases for 8 consecutive years, with $37.5 million the latest figure, recorded in Q2 2026.

• Quarterly Operating Leases fell 12.42% year-over-year to $37.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $37.5 million (down 12.42% YoY) and the FY2025 annual result came in at $41.6 million, up 108.54% from the prior year.
• Operating Leases slipped to $37.5 million in Q2 2026 per NVCR's latest filing, from $39.5 million in the prior quarter.
• Over the last five years, Operating Leases for NVCR reached as high as $42.9 million in Q2 2025 and fell as low as $13.4 million in Q2 2022.
• A 5-year average of $26.9 million and a median of $21.9 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2024 — Operating Leases dropped 27.17% — and 2025, when it surged 108.54%.
• Year by year, Operating Leases stood at $18.8 million in 2022, then jumped by 46.15% to $27.4 million in 2023, then slipped by 27.17% to $20.0 million in 2024, then jumped by 108.54% to $41.6 million in 2025, then decreased by 9.89% to $37.5 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $37.5 million, $39.5 million, and $41.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.